Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

PURPOSE: Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior Prostate Cancer Clinical Trials Working Groups....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Scher, Howard I., Morris, Michael J., Stadler, Walter M., Higano, Celestia, Basch, Ethan, Fizazi, Karim, Antonarakis, Emmanuel S., Beer, Tomasz M., Carducci, Michael A., Chi, Kim N., Corn, Paul G., de Bono, Johann S., Dreicer, Robert, George, Daniel J., Heath, Elisabeth I., Hussain, Maha, Kelly, Wm. Kevin, Liu, Glenn, Logothetis, Christopher, Nanus, David, Stein, Mark N., Rathkopf, Dana E., Slovin, Susan F., Ryan, Charles J., Sartor, Oliver, Small, Eric J., Smith, Matthew Raymond, Sternberg, Cora N., Taplin, Mary-Ellen, Wilding, George, Nelson, Peter S., Schwartz, Lawrence H., Halabi, Susan, Kantoff, Philip W., Armstrong, Andrew J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2016
Matèries:
Special Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872347/
https://ncbi.nlm.nih.gov/pubmed/26903579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.2702
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars